Literature DB >> 28973412

Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.

Catherine Godfrey1, Michael C Thigpen1, Keith W Crawford1, Patrick Jean-Phillippe1, Deenan Pillay2, Deborah Persaud3, Daniel R Kuritzkes4, Mark Wainberg5, Elliot Raizes6, Joseph Fitzgibbon1.   

Abstract

Entities:  

Keywords:  HIV; HIV drug resistance; antiretroviral; drug resistance; genotyping; human immunodeficiency virus; low/middle-income countries; virological failure

Mesh：

Substances：

Year:  2017        PMID： 28973412      PMCID： PMC5853929          DOI： 10.1093/infdis/jix137

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  21 in total

1.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.

Authors:  M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  Pretreatment HIV-1 drug resistance in Africa.

Authors:  Raph L Hamers; Cissy Kityo; Kim Ce Sigaloff; Tobias F Rinke de Wit
Journal:  Lancet Infect Dis       Date:  2013-06       Impact factor: 25.071

3.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

4.  A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.

Authors:  Raphaël Mourad; François Chevennet; David T Dunn; Esther Fearnhill; Valerie Delpech; David Asboe; Olivier Gascuel; Stéphane Hue
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

Review 5.  Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring.

Authors:  Trevor Peter; Dennis Ellenberger; Andrea A Kim; Debrah Boeras; Tsehaynesh Messele; Teri Roberts; Wendy Stevens; Ilesh Jani; Alash'le Abimiku; Nathan Ford; Zachary Katz; John N Nkengasong
Journal:  Lancet Infect Dis       Date:  2016-10-20       Impact factor: 25.071

6.  Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake Victoria.

Authors:  Jamirah Nazziwa; Harr Freeya Njai; Nicaise Ndembi; Josephine Birungi; Fred Lyagoba; Asiki Gershim; Jessica Nakiyingi-Miiro; Leslie Nielsen; Juliet Mpendo; Annet Nanvubya; Jan Debont; Heiner Grosskurth; Anatoli Kamali; Janet Seeley; Pontiano Kaleebu
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05       Impact factor: 2.205

7.  Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.

Authors:  Louise Kuhn; Gillian Hunt; Karl-Günter Technau; Ashraf Coovadia; Johanna Ledwaba; Sam Pickerill; Martina Penazzato; Silvia Bertagnolio; Claude A Mellins; Vivian Black; Lynn Morris; Elaine J Abrams
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

8.  Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.

Authors:  Ravindra K Gupta; Michael R Jordan; Binta J Sultan; Andrew Hill; Daniel H J Davis; John Gregson; Anthony W Sawyer; Raph L Hamers; Nicaise Ndembi; Deenan Pillay; Silvia Bertagnolio
Journal:  Lancet       Date:  2012-07-23       Impact factor: 79.321

9.  How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact.

Authors:  Dobromir T Dimitrov; Marie-Claude Boily; Timothy B Hallett; Jan Albert; Charles Boucher; John W Mellors; Deenan Pillay; David A M C van de Vijver
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

10.  SHIVA - a web application for drug resistance and tropism testing in HIV.

Authors:  Mona Riemenschneider; Thomas Hummel; Dominik Heider
Journal:  BMC Bioinformatics       Date:  2016-08-22       Impact factor: 3.169
View more
  13 in total

1.  Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20.

Authors:  Daniel W Kneller; Johnson Agniswamy; Arun K Ghosh; Irene T Weber
Journal:  Biochem Biophys Res Commun       Date:  2019-08-29       Impact factor: 3.575

2.  HIV primary drug resistance and associated HIV risk factors among HIV positive blood donors in Brazil from 2007 to 2017.

Authors:  Carlos Henrique Valente Moreira; Tassila Salomon; Cecília S Alencar; Thelma T Gonçalez; Ester C Sabino; Liliana Preiss; Paula Loureiro; Maria Esther Lopes; Carolina Miranda Teixeira; Mariana Mundim; Anna Barbara Carneiro-Proietti; Cesar de Almeida-Neto; Brian Custer
Journal:  Transfus Med       Date:  2021-03-04       Impact factor: 2.057

3.  The global burden of HIV-1 drug resistance in the past 20 years.

Authors:  Maurizio Zazzi; Hui Hu; Mattia Prosperi
Journal:  PeerJ       Date:  2018-05-25       Impact factor: 2.984

4.  Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.

Authors:  Nicholas Silver; Mary Paynter; Georgina McAllister; Maureen Atchley; Christine Sayir; John Short; Dane Winner; David J Alouani; Freddie H Sharkey; Kicki Bergefall; Kate Templeton; David Carrington; Miguel E Quiñones-Mateu
Journal:  AIDS Res Ther       Date:  2018-11-08       Impact factor: 2.250

5.  HIV drug resistance in patients in China's national HIV treatment programme who have been on first-line ART for at least 9 months.

Authors:  Pengtao Liu; Hui Xing; Lingjie Liao; Yi Feng; Xuebing Leng; Jing Wang; Wei Kan; Jing Yan; Yang Li; Zhongbao Zuo; Yinghui You; Yuhua Ruan; Yiming Shao
Journal:  AIDS Res Ther       Date:  2020-03-05       Impact factor: 2.250

6.  Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PRS17.

Authors:  Johnson Agniswamy; Daniel W Kneller; Arun K Ghosh; Irene T Weber
Journal:  Biochem Biophys Res Commun       Date:  2021-06-07       Impact factor: 3.322

7.  Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication.

Authors:  Helene Borrmann; Rhianna Davies; Matthew Dickinson; Isabela Pedroza-Pacheco; Mirjam Schilling; Alun Vaughan-Jackson; Andrea Magri; William James; Peter Balfe; Persephone Borrow; Jane A McKeating; Xiaodong Zhuang
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

8.  Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.

Authors:  Shibani S Mukerji; Vikas Misra; David R Lorenz; Hajime Uno; Susan Morgello; Donald Franklin; Ronald J Ellis; Scott Letendre; Dana Gabuzda
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

9.  The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030.

Authors:  Emmanuel Ndashimye; Eric J Arts
Journal:  Infect Dis Poverty       Date:  2019-08-02       Impact factor: 4.520

10.  High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.

Authors:  Amalia Girón-Callejas; Claudia García-Morales; Ricardo Mendizabal-Burastero; Matilde Román; Daniela Tapia-Trejo; Marissa Pérez-García; Verónica S Quiroz-Morales; Sandra I Juárez; Giovanni Ravasi; Carlos Vargas; René Gutiérrez; Luz Romero; Aleyda Solórzano; Edgar Sajquim; Sanny Northbrook; Santiago Ávila-Ríos; Gustavo Reyes-Terán
Journal:  J Int AIDS Soc       Date:  2019-12       Impact factor: 5.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.